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DICER1 is an RNase endonuclease important for pro-
duction of microRNAs, which regulate multiple protein-
coding genes involved in growth and development. It has
been linked to several tumors including pleuropulmonary
blastoma (PPB), cystic nephroma, ovarian Sertoli-Leydig
cell tumors and thyroid neoplasia. Most of the manifesta-
tions of DICER1 mutations occur in young children, ado-
lescents and young adults; only thyroid neoplasia are
diagnosed throughout adulthood. Although mutations in
this gene behave as autosomal dominant tumor suppres-
sor genes, the penetrance of the various tumors is highly
variable, rendering screening and genetic counseling
challenging.
We have recently hypothesized that mutations in this
gene are also responsible for the very rare but often fatal
cases of infant (< 3y) Cushing Disease, which can be
missed initially because of absent or only minimal signs
of intracranial hypertension and hypercortisolemia in this
age group. Eye signs, such as strabismus or proptosis,
may be the first manifestations of these tumors. The
ACTH-producing pituitary tumors seen in these infants
have a histopathology and electron microscopy that has
been termed pituitary blastoma. The incomplete pene-
trance of this and the other manifestations of the syn-
drome makes the involvement of additional predisposing
factors highly likely, candidates of which are under
investigation.
This presentation will highlight the cardinal features of
this new familial cancer syndrome, review the molecular
biology of DICER1, consider additional polygenic influ-
ences on tumor development and discuss the current
recommendations for following these families.
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